Genentech has licensed HM17321 outside South Korea for $190 million upfront and up to about $2.3 billion in total potential payments, betting on a UCN2 mechanism designed to reduce fat while preserving lean mass.
RenovoRx reports 51% targeted gemcitabine extraction with TAMP in pancreatic cancer. See what the data mean ahead of TIGeR-PaC results.
Japan expands ORLADEYO to children aged 2 to under 12 as BioCryst Pharmaceuticals builds its global HAE franchise. See what comes next.
FDA expands Ziihera into first-line HER2-positive gastroesophageal cancer. See how the approval could reshape treatment and Zymeworks growth.
The blood-brain barrier protects neurons by tightly controlling molecular traffic, but the same biology excludes many antibodies, enzymes and nucleic-acid medicines. Drug developers are increasingly hijacking the barrier’s own transport systems rather than trying simply to disrupt it.
A new US patent allowance broadens protection around RenovoRx’s dual-occlusion drug-delivery catheter as commercial revenue grows and the separate TIGeR-PaC drug-device programme moves toward 2027 data.
Johnson & Johnson has secured FDA approval for IMAAVY in warm autoimmune hemolytic anemia, giving eligible patients aged 12 and older the first treatment specifically approved in the United States for wAIHA.
FDA has cleared Freyja Healthcare’s second-generation VereSee, combining a 2 mm miniature laparoscope with visual entry technology intended to show anatomy during initial laparoscopic access.
The global EquilibriX-S trial will compare VMX-C001 with usual pharmacological care in approximately 800 patients taking Factor Xa inhibitors who require urgent high-bleeding-risk procedures.
Abcuro will use a $66 million Series D to start another potentially registrational study after MUSCLE failed overall but showed a prespecified signal in patients with less severe disease.